ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Open accessThe DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Abstract
Advanced Breast Cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality of life. Due to continuous research, several advances have been made, particularly for the HER-2-positive and for Luminal-like subtypes. Notwithstanding these advances, median overall survival of patients with ABC is still only 2e3 years, although the range is wide, and survival may be longer for patients treated in specialized institutions. Implementation of current knowledge is highly variable among countries and within each country. The use of treatment guidelines has been associated with a significant improvement in survival. This has been achieved mainly in early breast cancer. For ABC, and particularly metastatic breast cancer (MBC), less level 1 evidence exists and only recently have international consensus guidelines been developed (ABC1 e). The ABC Consensus Conference was created by the European School of Oncology (ESO) with the ambitious goal of improving outcomes for all patients with advanced breast cancer. Backed by strong political advocacy, ABC guidelines are seeking to improve standards of care, to raise awareness about how to best meet to the needs of this underserved group of patients, and to identify research priorities so that clinical research is focused on the most important areas of unmet need. Following the work of the ESO-ABC Task Force, created in 2005, and the successful undertaking of the 1st International Consensus Guidelines Conference on ABC (ABC1), held in November 2011, the 2nd International Consensus Conference for Advanced Breast Cancer (ABC2) took place in Lisbon, Portugal, on
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“For HER-2-positive LABC, anthracyclines should not be administered concurrently with trastuzumab since this approach does not increase the pCR rate, and it could increase the risk of cardiac toxicity, based largely on studies in the metastatic setting [35,36].”
BackgroundSelf-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · cited 2×
“lapatinib plus capecitabine in the subset of 118 patients who were randomized in the first-line setting, having relapsed on or within 6 months of adjuvant trastuzumab, appeared similar to the effect seen in the overall trial [100].”
BackgroundResultSelf-citationEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 1×
“The mTOR inhibitor everolimus when added to exemestane, in patients progressing on non-steroidal aromatase inhibitor, provided a significant PFS prolongation of about 5 months [89,90].”
BackgroundSelf-citationPertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532 · cited 1×
“The CLEOPATRA trial [96,97]; showed superior results, in terms of PFS (18.”
ResultEarly palliative care for patients with advanced cancer: a cluster-randomised controlled trial
Zimmermann, C., Swami, N., Krzyzanowska, M., Hannon, B., Leighl, N., Oza, A., Moore, M., Rydall, A., Rodin, G., Tannock, I., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62416-2 · Cited by 1,781 · cited 1×
“The multidisciplinary approach of ABC should encompass early in the history of the disease not only physical, but also functional, social, psychological, and spiritual, domains [25–27].”
BackgroundMiller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
ResultSelf-citationGrading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
Guyatt, G., Gutterman, D., Baumann, M. H., Addrizzo-Harris, D., Hylek, E. M., Phillips, B., Raskob, G., Lewis, S. Z., & Schünemann, H. (2006) · Chest · doi:10.1378/chest.129.1.174 · Cited by 1,220 · cited 1×
“Table 1 describes the grading system used [15].”
MethodCortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094 · cited 1×
“Eribulin has provided an OS benefit in heavily pretreated patients (up to 5 lines of treatment) [115] and similar PFS and OS results to capecitabine after prior treatment with an anthracycline and taxane [116].”
ResultSelf-citationRobert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
Resultvon Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J. U., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,022
Research works printed but not linked: 2
- Handesman D Androgen Actions and Pharmacologic Uses, Endocrinology 2001 Philadelphia WB Saunders 2232 2242
- Wildiers H Kim SB Gonzalez-Martin A T-DM1 for HER2-positive metastatic breast cancer (MBC): primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice 2013 Presented at the European Cancer Congress September 27–October 1 Amsterdam, The Netherlands (abstr LBA15)
Cited by
Items 501–540 of 540
Electrochemotherapy of Breast Cancer
Campana, L. G., Matthiessen, L. W., Snoj, M., & Serša, G. (2017) · Springer eBooks · doi:10.1007/978-3-319-48848-6_76
Chemotherapy Regimens in the Adjuvant and Advanced Disease Settings
Hart, C. D., Biganzoli, L., & Leo, A. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-48848-6_46
Self-citationThe Role of Surgery to the Primary Cancer in Stage IV Disease
Khan, S. A., & Odele, P. (2017) · Springer eBooks · doi:10.1007/978-3-319-56673-3_55
Role of Surgery in Lung Metastases from Breast Cancer
Shackcloth, M. J., & Love, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-56673-3_53
Ueno, N., Kuroda, H., Abe, A., Kubota, K., Kato, H., & Imai, Y. (2017) · International Surgery · doi:10.9738/intsurg-d-16-00255.1
Imyanitov, E. N., & Semiglazova, Т. Y. (2017) · Tumors of female reproductive system · doi:10.17650/1994-4098-2017-13-4-34-43
Advanced-Stage Breast Cancer Radiotherapy
İbiş, K., & Küçücük, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-96947-3_21
INFERRED SURVIVAL ANALYSIS OF METASTATIC BREAST CANCER IN A BRAZILIAN EXTERNAL LIBRARY
Debiasi, M., Simon, S. D., Preger, L., Cassoli, L., & Barrios, C. (2018) · Brazilian Journal of Oncology · doi:10.5935/2526-8732.20180008
Self-citationUntch, M., Würstlein, R., Marschner, N. W., Lüftner, D., Augustin, D., Briest, S., Ettl, J., Haidinger, R., Müller, L., Müller, V., et al. (2018) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-0797-4596
“[4] Cardoso F, Costa A, Norton L et al.”
BackgroundSelf-citationSánchez‐Rovira, P., Zamora, P. M., Bofill, J. S., Morales, S. M., Martínez-Jáñez, N., de Dueñas, E. M., Lluch, A. M., Illarramendi, J. J., Gómez-Pardo, P., Gregori, J. G., et al. (2019) · Journal of Drug Assessment · doi:10.1080/21556660.2019.1604375
Menshikova, S. F., Фролова, М. А., Глазкова, Е. В., & Stenina, M. B. (2018) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-19-28-30
“Наличие висцерального поражения и множественных метастазов в костях при отсутствии признаков висцерального криза не является противопоказанием к назначению ГТ [2].”
Артамонова, Е. В., & Kovalenko, E. I. (2019) · Tumors of female reproductive system · doi:10.17650/1994-4098-2019-15-2-30-41
“Вторичная (приобретенная) гормонорезистентность регистрируется при прогрессировании болезни после первых 2 лет адъювантной ГТ и до 1 года после ее окончания, а также при прогрессировании после первых 6 мес одной линии ГТ, проводимой по поводу мРМЖ [17].”
Clinical aspects of the use of ribociclib
Маркович, А. А., Kalugin, M. V., Гордеева, О. О., & Yakoobova, M. Z. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-9-44-56
Bone metastases at initial diagnosed breast cancer — A retrospective study based on SEER databasePreprint
Wang, Z., Tang, X., Zhang, Q., Wu, X., Yang, M., Jin, Z., & Wang, D. (2019) · Research Square · doi:10.21203/rs.2.10918/v1
“Because of lacking existed evidence, there is no recommendation for routine assessment or continued reassessment of bone metastases(8, 9).”
BackgroundRole of CDK4/6 inhibitors in metastatic hormon positive HER2 negative breast cancer treatment
Ban, M., Strikić, A., Miše, B. P., & Vrdoljak, E. (2019) · Liječnički vjesnik · doi:10.26800/lv-141-1-2-6
Quintero-Ortíz, M. A., Briceño-Morales, X., Sánchez-Castillo, O., Velásquez, J. C., Bonilla, C., Guzmán-Abisaab, L., Cervera, S., Bruges, R. E., Ángel-Aristizábal, J., Duarte, C., et al. (2021) · Revista Colombiana de Cancerología · doi:10.35509/01239015.747
Mishchenko, O. Y., Greshko, Y. I., Оstashko, V. F., & Berezniakov, A. (2021) · Likarska sprava · doi:10.31640/jvd.3-4.2021(12
Ryan, C. (2017) · British Journal of Nursing · doi:10.12968/bjon.2017.26.sup16a.s4
Marmé, F. (2016) · Springer eBooks · doi:10.1007/978-3-319-46356-8_20
Ryan, C., Burcombe, R. J., & Coleby, T. (2017) · British Journal of Nursing · doi:10.12968/bjon.2017.26.sup16a.s3
(2016) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2016.10.015
Locoregional treatment in de novo metastatic breast cancer: a retrospective cohort studyPreprint
Jianna, S., Lingjun, K., Nana, F., Liu, H., & Chongxi, R. (2020) · Research Square · doi:10.21203/rs.3.rs-70080/v1
“Their overall survival (OS) was approximately 16 to 29 months [6].”
BackgroundLocoregional Treatment in De Novo Metastatic Breast Cancer: A Retrospective Cohort StudyPreprint
Jianna, S., Lingjun, K., Nana, F., Liu, H., & Chongxi, R. (2020) · Research Square · doi:10.21203/rs.3.rs-125308/v1
Hou, L. M., Wu, N., Su, X., Tan, Q., Li, J., & Chen, M. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4169432
Narvaez, D. P., Waisberg, F., Soulé, T., Angel, M. O., Bruno, L. I., Girotti, M. R., Pupareli, C. S., Chacon, M. R., & Petracci, F. E. (2022) · ecancermedicalscience · doi:10.3332/ecancer.2022.1448
“Considering the observed primary hormone resistance according to European School of Oncology- European Society for Medical Oncology (ESO-ESMO) 2016 Consensus Guidelines, and the rapid visceral progression, combined chemotherapy was selected with docetaxel plus capecitabine [1].”
BackgroundZiobro, M., & Grela-Wojewoda, A. (2023) · Biomedicines · doi:10.3390/biomedicines11020510 · Cited by 3
“While 5 years ago, monotherapy with aromatase inhibitors or tamoxifen, or fulvestrant, was the standard first-line treatment [8,9]; today, the treatment of choice is endocrine therapy with aromatase inhibitors or fulvestrant in combination with CDK4/6 inhibitors [10,11].”
BackgroundIn Vitro Cytotoxicity of Gallic Acid Derivatives (Alkyl gallates) Against Breast MCF-7 Cancer Cells
Arsianti, A., Dorothea, M., Syafira, N., Tony, A., & Bahtiar, A. (2022) · doi:10.2991/978-94-6463-062-6_26
HER2 positive breast cancer and its treatment with trastuzumab, where are we now?
Lokvančić, H. (2022) · Bioengineering Studies · doi:10.37868/bes.v3i2.id239
Editorial: Global excellence in nuclear medicine: North America
Jha, A., & Civelek, A. C. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1300179
(2023) · Liječnički vjesnik · doi:10.26800/lv-145-supl6-3
Toader, I. D., & Cruzado, J. A. (2024) · Psicooncología · doi:10.5209/psic.94813
Sánchez, R. S., Jiménez, A. D. G., Luquin, T. A., Arnau, I. M., & Herrezuelo, I. P. (2024) · Revista de Senología y Patología Mamaria · doi:10.1016/j.senol.2024.100629
Andrade, M. D. O., Felix, V. H., Testa, L., & Bonadio, R. C. (2025) · ecancermedicalscience · doi:10.3332/ecancer.2025.1894 · Cited by 1
“Up to nearly one-third of cases will pres-ent with metastatic disease in the course of their diagnosis, which may evolve into a critical scenario when there is organ dysfunction secondary to neoplastic dissemination to vital organs, a condition known as visceral crisis (VC) [1–3].”
Mehta, S., Kwong, J., Lam, C. J. K., & Feinberg, B. A. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf106
“19 CT is recommended in these patients as an urgent need to achieve the greatest possible tumor response in the shortest time.”
Lema, M., Herazo, F., Egurrola, J., Ortiz, D. M., López, J. C., Quintero, N. E. L., Ramírez, D. M. G., Yepes, A., Yepes, C. V., Castrillón, M. B., et al. (2025) · Revista Colombiana de Hematología y Oncología · doi:10.51643/22562915.769
Toledo, F. V., Meletti, J. F. A., Silva, L. M. C., Serra, N. M. M., Mendonça, M. N. P. S., Guerra, P. H. C., & Pinto, C. A. L. (2026) · Brazilian Journal of Anesthesiology (English Edition) · doi:10.1016/j.bjane.2026.844749
“2-4 Consequently, the management of acute postoperative pain represents a fundamental component of care, as patients often experience a combination of nociceptive and neuropathic pain.”
Louault, K. (2018) · theses.fr (ABES) · doi:10.70675/0aef1137z5689z4922z8455zdbe4b757612c
Raghavendra, A. S., Qiao, W., Shen, Y., Damodaran, S., Hunt, K. K., & Tripathy, D. (2026) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2026.101482
Cardoso, F., Ribeiro, J. M., Schumacher-Wulf, E., Swain, S. M., Paluch–Shimon, S., Penault-Llorca, F. M., Lin, N., Francis, P. A., Kuper-Hommel, M. J. J., May, A. M., et al. (2026) · The Breast · doi:10.1016/j.breast.2026.104921 · Cited by 2
Self-citation
Metadata
- Authors
- Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., Cardoso, M. J., Cufer, T., El Saghir, N., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Giordano, S. H., Gligorov, J., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Krop, I., Kyriakides, S., Lin, U. N., Mayer, M., Merjaver, S. D., Nordström, E. B., Pagani, O., Partridge, A., Penault-Llorca, F., Piccart, M. J., Rugo, H., Sledge, G., Thomssen, C., van't Veer, L., Vorobiof, D., Vrieling, C., West, N., Xu, B., & Winer, E.
- Affiliations
- Centro Champalimaud (PT)
- European School of Oncology (CH)
- Memorial Sloan Kettering Cancer Center (US)
- Gdańsk Medical University (PL)
- Clinique de Genolier (CH)
- Institut Gustave Roussy (FR)
- Pontifícia Universidade Católica do Rio Grande do Sul (BR)
- Karolinska University Hospital (SE)
- Fondazione Sandro Pitigliani (IT)
- Duke University (US)
- Champalimaud Foundation (PT)
- Brighton and Sussex Medical School (GB)
- Europa Donna (IT)
- Peter MacCallum Cancer Centre (AU)
- BC Cancer Agency (CA)
- The University of Texas MD Anderson Cancer Center (US)
- Université Pierre-et-Marie-Curie (FR)
- European Institute of Oncology (IT)
- Ludwig-Maximilians-Universität München (DE)
- The University of Sydney (AU)
- Sheba Medical Center (IL)
- Dana-Farber Cancer Institute (US)
- University of Michigan (US)
- Europa Donna (GE)
- Istituto Oncologico della Svizzera Italiana (CH)
- Centre Jean Perrin (FR)
- Institut Jules Bordet (BE)
- University of California, San Francisco (US)
- Indiana University (US)
- Martin Luther University Halle-Wittenberg (DE)
- Cardiff and Vale University Health Board (GB)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Cardoso, F.
- ORCID
- Cardoso, F.
- Costa, A.
- Norton, L.
- Senkus, E.
- Aapro, M.
- André, F.
- Barrios, C.H.
- Bergh, J.
- Biganzoli, L.
- Cardoso, M.J.
- Fallowfield, L.
- Francis, P.
- Gelmon, K.
- Giordano, S.H.
- Gligorov, J.
- Harbeck, N.
- Houssami, N.
- Hudis, C.
- Kaufman, B.
- Krop, I.
- Pagani, O.
- Partridge, A.
- Penault-Llorca, F.
- Piccart, M.J.
- Rugo, H.
- Sledge, G.
- Thomssen, C.
- Vorobiof, D.
- Vrieling, C.
- Xu, B.
- Winer, E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 25
- Issue
- 10
- Pages
- 1871-1888
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC4176456
- OpenAlex
- W2127287298
- Cited by
- 540
- References
- 143
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 15 · 2023: 23 · 2022: 20 · 2021: 24 · 2020: 38 · 2019: 37 · 2018: 57 · 2017: 107 · 2016: 124 · 2015: 84 · 2014: 2
- FWCI
- 33.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 1878 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- Sussex Research Online (University of Sussex) (submittedVersion, cc-by-nc-nd)
- OAR@UM (University of Malta) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Figshare (submittedVersion, cc-by-nc-nd)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- advanced breast cancer, metastatic breast cancer, treatment guidelines, HER2-positive breast cancer, luminal breast cancer, overall survival, quality of life, standard of care, unmet medical needs, research priorities
- MeSH terms
- Breast Neoplasms, Female, Humans, Treatment Outcome, Guidelines as Topic, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.